Literature DB >> 17987049

Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease.

I Cancelli1, L Valentinis, G Merlino, M Valente, G L Gigli.   

Abstract

Emerging evidence suggests that psychosis in persons with Alzheimer's disease (AD) may be linked to the cholinergic deficit associated with the disease. This study sought to evaluate whether anticholinergic (ACH) drugs could be a risk factor for psychosis onset. A total of 230 patients affected with probable AD were recruited. Data on behavioral and psychological symptoms were collected using the Neuropsychiatric Inventory, and diagnosis of psychosis was performed. Patients were divided into those who used ACH drugs and those who used non-ACH drugs. Those using ACH drugs (18.3%) were more likely to have psychosis than those using non-ACH drugs (odds ratio (OR)=2.52; 95% confidence interval (CI), 1.27-5.00); this association remained significant even after adjusting for potential confounding variables (OR=2.13; 95% CI, 1.03-4.43). Our data suggest that patients with AD are frequently treated with ACH drugs and that ACH drug intake should be regarded as a potential risk factor for psychosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17987049     DOI: 10.1038/sj.clpt.6100435

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews.

Authors:  Tomas J Welsh; Veronika van der Wardt; Grace Ojo; Adam L Gordon; John R F Gladman
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

Review 2.  Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes?

Authors:  Tanja Mayer; Walter E Haefeli; Hanna M Seidling
Journal:  Eur J Clin Pharmacol       Date:  2015-09-08       Impact factor: 2.953

3.  Capturing side-effect of medication to identify persons at risk of delirium.

Authors:  Fulvio Lauretani; Gian Paolo Ceda; Marcello Maggio; Anna Nardelli; Marsilio Saccavini; Luigi Ferrucci
Journal:  Aging Clin Exp Res       Date:  2010 Oct-Dec       Impact factor: 3.636

Review 4.  Animal Models of Psychosis in Alzheimer Disease.

Authors:  Josh M Krivinko; Jeremy Koppel; Alena Savonenko; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-05-17       Impact factor: 4.105

5.  Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, cross-sectional study.

Authors:  Marie-Pierre Fortin; Isabelle Rouch; Virginie Dauphinot; Claire Gédéon; Stella Genthon; Marc Bonnefoy; Pierre Krolak-Salmon
Journal:  Drugs Aging       Date:  2011-03-01       Impact factor: 3.923

6.  Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.

Authors:  Isabelle Carrière; Annie Fourrier-Reglat; Jean-François Dartigues; Olivier Rouaud; Florence Pasquier; Karen Ritchie; Marie-Laure Ancelin
Journal:  Arch Intern Med       Date:  2009-07-27

Review 7.  Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients.

Authors:  Iacopo Cancelli; Massimiliano Beltrame; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Neurol Sci       Date:  2009-02-20       Impact factor: 3.307

Review 8.  Association between anticholinergic drug burden and mortality in older people: a systematic review.

Authors:  Sheraz Ali; Gregory M Peterson; Luke R Bereznicki; Mohammed S Salahudeen
Journal:  Eur J Clin Pharmacol       Date:  2019-12-12       Impact factor: 2.953

9.  An anticholinergic burden score for German prescribers: score development.

Authors:  Esther Katharina Kiesel; Yvonne Marina Hopf; Michael Drey
Journal:  BMC Geriatr       Date:  2018-10-11       Impact factor: 3.921

Review 10.  Anticholinergic Drugs in Geriatric Psychopharmacology.

Authors:  Jorge López-Álvarez; Julia Sevilla-Llewellyn-Jones; Luis Agüera-Ortiz
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.